Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28940838 | 1.00 | LGALS3 (0.59) | LGALS3 | |
| SCHEMBL28742217 | 0.92 | LGALS3 (0.58) | LGALS3 | |
| SCHEMBL28742189 | 0.92 | LGALS3 (0.57) | LGALS3 | |
| SCHEMBL29448624 | 0.92 | LGALS3 (0.60) | LGALS3 | |
| SCHEMBL28742271 | 0.92 | LGALS3 (0.60) | LGALS3 | |
| SCHEMBL22981562 | 0.90 | LGALS3 (0.49) | LGALS3 | |
| SCHEMBL29448613 | 0.90 | LGALS3 (0.49) | LGALS3 | |
| SCHEMBL22982621 | 0.88 | LGALS3 (0.59) | LGALS3 | |
| SCHEMBL28742199 | 0.88 | LGALS3 (0.54) | LGALS3 | |
| SCHEMBL22982132 | 0.87 | LGALS3 (0.52) | LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291519-B2 | 2-hydroxycycloalkane-1-carbamoyl | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-06 | — | — | US | claimed |
| EP-4013751-B1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-22 | — | — | EP | claimed |
| US-20220324847-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-13 | — | — | US | claimed |
| EP-4013751-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-22 | — | — | EP | claimed |
| CN-114269737-A | 2-hydroxycycloalkane-1-carbamoyl derivatives | 爱杜西亚药品有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-12291519-B2 | 2-hydroxycycloalkane-1-carbamoyl | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-06 | — | — | US | disclosed |
| EP-4013751-B1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-22 | — | — | EP | disclosed |
| US-20220324847-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-13 | — | — | US | disclosed |
| EP-4013751-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114269737-A | 2-hydroxycycloalkane-1-carbamoyl derivatives | 爱杜西亚药品有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291519-B2 | 2-hydroxycycloalkane-1-carbamoyl | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885 |
| US-20220324847-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.